PUBLIC COMPANY
savePathos AI Inc
updated 5mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnershipAI-driven biotech Pathos AI has corralled a $237 million Series E at a $3 billion valuation, the New York-based company said on Wednesday. The large fundraise comes in below the $300 million that t…endpoints · 27d ago
- BMS leads Pathos AI's $237M series E alongside Alzheimer's link-upPathos AI has closed a $237 million series E round led by pharma giant Bristol Myers Squibb on the same day that the two companies signed a cutting-edge Alzheimer's disease-focused collaboration.fiercebiotech · 1mo ago
- Pathos inks BMS, Tempus collabs to apply agentic AI in Alzheimer's clinical developmentPathos AI has signed two new collaboration deals aimed at developing drugs for neurological conditions such as Alzheimer's disease, one with pharma giant Bristol Myers Squibb and another with Tempu…fiercebiotech · 1mo ago
- J&J pharma leader to retire; Krystal slumps on gene therapy missJennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.biopharma_dive · 3mo ago
- Pathos inks back-to-back cancer contracts with AstraZeneca, China’s AlphamabPathos AI could pay more than $2 billion to a Jiangsu Alphamab Biopharmaceuticals subsidiary for a late-stage bispecific antibody-drug conjugate for breast cancer, while the financial details of th…biospace · 3mo ago
- Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pactPathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate from China’s Alphamab Oncology, while adding a Big Pharma partner in the form of AstraZeneca.fiercebiotech · 3mo ago
- Pathos does deals with AstraZeneca, China's Alphamab, seeks up to $300M Series EPathos AI is firing on all cylinders. The technology and drug development company told Endpoints News that it signed a major antibody-drug conjugate deal with a Chinese biotech and teamed up with i…endpoints · 3mo ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that